Vasogen says VPO25 prevents some detrimental neurological effects of Alzheimer's

By Ted A. Knutson

Washington, Nov. 17 - Vasogen Inc.'s VP025 has the ability to prevent the detrimental neurological effects of chronic beta-amyloid exposure in a model of Alzheimer's disease, the company said in a 6-K filing with the Securities and Exchange Commission.

"We believe that the data presented, demonstrating the ability of VP025 to preserve memory and learning function in the presence of chronic beta-amyloid exposure, provides further evidence supporting the potential of VP025 as a new treatment for Alzheimer's and other dementias," stated Dr. Anthony Bolton, Vasogen's chief scientific officer, in a news release. "Having successfully completed our phase I program, we look forward to moving VP025 into phase II clinical development in neuro-inflammatory disease."

The company's findings were presented Wednesday at Neuroscience 2005, the Society for Neuroscience's 35th annual meeting in Washington, D.C.

Mississauga, Ont.-based Vasogen is focused on the development of technologies targeting chronic inflammation underlying cardiovascular and neurological disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.